Robert Cupelo, MD, Principal Investigator in Syracuse, NY, shares his firsthand insights into the evolving landscape of Alzheimer’s treatment. Nearly two years after the FDA’s approval of lecanemab (Leqembi), and with the subsequent approval of donanemab (Kisunla), researchers are making crucial steps forward in the fight against disease progression and for disease prevention.
In this thought-provoking BioSpace piece, Dr. Cupelo considers the need for a multidrug approach to effectively combat this challenging disease.
Read it now: https://www.biospace.com/drug-development/opinion-the-cocktail-recipe-that-will-cure-alzheimers
#Alzheimers #ClinicalTrials #ClinicalResearch #PrincipalInvestigators
